Company intelligence / Profile preview

Steriscience

Bangalore, Karnataka, India

Ownership: Private
Development stage: Other

Overview

Steriscience has developed and commercialized sterile injectable products globally. As of 2024, it has 18 approved ANDAs (13 acquired, 5 in-house developed), operates multiple advanced manufacturing sites with approvals from US FDA, EU GMP, and Health Canada, and supplies high-quality medications to key international markets. The company has expanded by launching products in the US (since May 2022) and Europe, and has completed Phase 1 R&D on over 30 programs, with a focus on complex and ready-to-use injectables.[2][3][5][6][9][10]

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeBiologicDrug-device combination
Industry: Biotech

Partnerships

MylanOneSource Specialty PharmaBrooks’ Carbapenems

Beyond the preview

Go deeper on Steriscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Steriscience.

Explore the full profile